At ESC26, CRISPR Therapeutics said it will pursue the highest dose of its lipid-lowering gene editing therapy after presenting mixed durability results from early-stage data around a year after dosing. The company framed the update as a path to improve durability and maximize pharmacodynamic impact. In parallel, the Ziihera/diagnostic ecosystem expansion and other cardiometabolic developments indicate gene and RNA modalities are competing for clinical space where outcome differentiation matters. CRISPR’s dose strategy signals continued reliance on durability optimization rather than purely seeking earlier efficacy signals.